These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17119927)

  • 41. The inhibitory effect of copper ions on lymphocyte Kv1.3 potassium channels.
    Teisseyre A; Mozrzymas JW
    J Physiol Pharmacol; 2006 Jun; 57(2):301-14. PubMed ID: 16845233
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations.
    Caballero R; Gómez R; Núñez L; Moreno I; Tamargo J; Delpón E
    Cardiovasc Res; 2004 Dec; 64(3):457-66. PubMed ID: 15537499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues.
    Straub SV; Perez SM; Tan B; Coughlan KA; Trebino CE; Cosgrove P; Buxton JM; Kreeger JM; Jackson VM
    Am J Physiol Endocrinol Metab; 2011 Aug; 301(2):E380-90. PubMed ID: 21586699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dihydropyridine Ca2+ channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K+ channels expressed in HEK293 cells.
    Hatano N; Ohya S; Muraki K; Giles W; Imaizumi Y
    Br J Pharmacol; 2003 Jun; 139(3):533-44. PubMed ID: 12788813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers.
    Valenzuela C; Delpón E; Tamkun MM; Tamargo J; Snyders DJ
    Biophys J; 1995 Aug; 69(2):418-27. PubMed ID: 8527655
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genistein inhibits the activity of kv1.3 potassium channels in human T lymphocytes.
    Teisseyre A; Michalak K
    J Membr Biol; 2005 May; 205(2):71-9. PubMed ID: 16283587
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of rosiglitazone, an antidiabetic drug, on Kv3.1 channels.
    Lee HM; Yoon SH; Kim MG; Hahn SJ; Choi BH
    Korean J Physiol Pharmacol; 2023 Jan; 27(1):95-103. PubMed ID: 36575937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of the activity of human lymphocyte Kv1.3 potassium channels by resveratrol.
    Teisseyre A; Michalak K
    J Membr Biol; 2006; 214(3):123-9. PubMed ID: 17557164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp.
    Wacker SJ; Jurkowski W; Simmons KJ; Fishwick CW; Johnson AP; Madge D; Lindahl E; Rolland JF; de Groot BL
    ChemMedChem; 2012 Oct; 7(10):1775-83. PubMed ID: 22473914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum albumin attenuates the open-channel blocking effects of propofol on the human Kv1.5 channel.
    Kojima A; Bai JY; Ito Y; Ding WG; Kitagawa H; Matsuura H
    Eur J Pharmacol; 2016 Jul; 783():117-26. PubMed ID: 27164421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation.
    Decher N; Kumar P; Gonzalez T; Pirard B; Sanguinetti MC
    Mol Pharmacol; 2006 Oct; 70(4):1204-11. PubMed ID: 16835355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Duloxetine blocks cloned Kv4.3 potassium channels.
    Choi JS; Hahn SJ
    Brain Res; 2012 Jul; 1466():15-23. PubMed ID: 22618310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.
    Gögelein H; Brendel J; Steinmeyer K; Strübing C; Picard N; Rampe D; Kopp K; Busch AE; Bleich M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Sep; 370(3):183-92. PubMed ID: 15340774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arachidonic acid potently inhibits both postsynaptic-type Kv4.2 and presynaptic-type Kv1.4 IA potassium channels.
    Angelova PR; Müller WS
    Eur J Neurosci; 2009 May; 29(10):1943-50. PubMed ID: 19453640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
    Perchenet L; Hilfiger L; Mizrahi J; Clément-Chomienne O
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1108-19. PubMed ID: 11504808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The glycosylation state of Kv1.2 potassium channels affects trafficking, gating, and simulated action potentials.
    Watanabe I; Zhu J; Sutachan JJ; Gottschalk A; Recio-Pinto E; Thornhill WB
    Brain Res; 2007 May; 1144():1-18. PubMed ID: 17324383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Voltage- and time-dependent block by perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel.
    Rampe D; Wang Z; Fermini B; Wible B; Dage RC; Nattel S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):444-9. PubMed ID: 7616429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The modulatory effect of zinc ions on voltage-gated potassium currents in cultured rat hippocampal neurons is not related to Kv1.3 channels.
    Teisseyre A; Mercik K; Mozrzymas JW
    J Physiol Pharmacol; 2007 Dec; 58(4):699-715. PubMed ID: 18195482
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tityustoxin-K(alpha) blockade of the voltage-gated potassium channel Kv1.3.
    Rodrigues AR; Arantes EC; Monje F; Stühmer W; Varanda WA
    Br J Pharmacol; 2003 Jul; 139(6):1180-6. PubMed ID: 12871837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
    Lagrutta A; Wang J; Fermini B; Salata JJ
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.